What are the Differences Between Juvederm® XC (Ultra 2, 3, 4) and Juvederm®?
The new Juvederm® XC formulation has lidocaine integrated and provides U.S patients with the same comfort that has been enjoyed by Canadians and Europeans for years. RxPad has been successfully distributing this improved product over the last two years, anxiously awaiting the official FDA-Approval. The new Juvederm® XC will provide U.S patients with their desired results and an improved level of comfort during the application process‡. The days of U.S patients having to painfully endure and dread their next Juvederm® application are finally over!
Juvederm® XC is hyaluronic acid gel which is eased into a patient’s skin by a healthcare professional. It helps restore the volume of a patient’s skin and will help alleviate facial wrinkles. Specifically, Juvederm® XC helps provide a smoother, more youthful look to a patient’s nasolabial folds and smile-lines*. Plus, according to Allergan, Juvederm® XC is the only hyaluronic acid to last up to 1 year†. A typical Juvederm® XC application takes less than 20 minutes. The changes are evident immediately and the experience of a Juvederm® injection is finally enjoyable with the official Juvederm® XC U.S introduction!
What is the Difference Between Juvederm® XC and Juvederm® Ultra 2, 3, and 4?
The only difference is the cosmetic appearance of the packaging. Allergan Inc. is a multinational manufacturer and packages their products according to the country of distribution. Juvederm® Ultra 2, 3, 4, are the marketing names for UK distribution, just as Juvederm® Ultra XC and Juvederm® Ultra Plus XC are the marketing names in the United States. Rest assured, the product you order from RxPad will always be the same product that you buy in the United States. The active ingredient found in the Juvederm® is FDA-approved and RxPad guarantees Allergan product authenticity and client satisfaction.
What are the Savings Offered by RxPad?
RxPad offers clients a 35% saving per syringe kit compared to the U.S manufacturer. Juvederm Ultra XC (Ultra 2) is priced as low as $239.00 per syringe kit (2 x 0.55mL) and Juvederm Ultra Plus XC (Ultra 3) is priced as low as $249.00 per syringe kit (2 x 0.55mL). The 35% saving includes the differential between the syringe kit sizes (0.55mL versus 0.8mL)!
Clinical Study: Juvederm Ultra versus Juvederm Ultra XC (Ultra 2)
**In a clinical study comparing JUVÉDERM® Ultra with and without lidocaine, 36 subjects received the product with lidocaine in 1 nasolabial fold and the product without lidocaine in the other. Subjects rated the level of pain during each injection. Pain was significantly less on the side that received JUVÉDERM® Ultra XC, and in comparing the 2 injections, 34 subjects (94%) found the lidocaine formulation to be less painful.**
For Additional Information Contact:
Michael Merriam
Senior Account Executive
RxPad
1-866-544-8208 ext: 115
michael.merriam@rxpad.biz
“Your Trusted Allergan Botox® and Juvederm® Source With An International Reach”
Copyright © 2010 RxPad.biz. All Rights Reserved. ® Trademarks Owned in the United States by Allergan Inc. RxPad.biz is not operated by, sponsored by, endorsed by, or affiliated with Allergan Inc., Allergan Ltd., or Allergan Pharmaceuticals in any way. RxPad.biz purchases Authentic Allergan Botox® from licensed European Wholesalers and guarantees official Allergan authenticity.References: *In the United States, JUVÉDERM® injectable gel is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). ‡Compared to the non-lidocaine JUVÉDERM® formulation. †Data on file, Allergan, Inc.; Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy DK. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of JUVÉDERM® injectable gel with and without lidocaine. J Cosmet Dermatol. 2009;8(3):205-210. Please see JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Patient Safety Information for more information. **(http://www.juvederm.com/professionals/pdf/Final%20Patient%20Labeling%20-%20Ultra%20XC.pdf)

0
Responses